PURPOSE:
We have previously validated the pre-clinical use of deferoxamine (DFO) as an osteogenic stimulant capable of preventing non-unions in irradiated mandible fractures. DFO indirectly bolsters bone formation by stimulating angiogenesis and restoring diminished vascularity within irradiated tissues. Despite this promise, there have been concerns regarding the use of DFO to treat osseous defects in head and neck cancer survivors due to its remarkable ability to induce angiogenesis and promote tissue vascularization. Because of its iron chelating mechanism of action, we subsequently demonstrated that DFO actually elicits toxic, anti-tumorigenic actions on MDA-1986 head and neck squamous cell carcinoma (HNSCC) in vitro and in vivo. Aside from iron's critical metabolic functions, it is also crucial for the survival of rapidly dividing cancer cells, and its removal intensely inhibits tumor formation. In essence, DFO kills cancer cells by depleting iron stores that these rapidly dividing cells require, while protecting angiogenic mechanisms and stimulating the normal growth of blood vessels in injured tissues.
To further investigate this line of inquiry, we surveyed the Alabama HNSCC patient survivorship TGCA database for iron related genes and found that Transferrin Receptor Protein (TFRC) and Ferritin Heavy Chain-1 (FTH-1) were significantly upregulated in HNSCC, suggesting that dysregulation of iron mediators play a role in HNSCC development. Based on these observations, we posited that DFO exposure would alter HNSCC iron-mediator expression.
METHODS:
We analyzed human MDA-1986 and UMSCC 108 HNSCC cells (HPV + and -cells, respectively) with and without DFO treatment (50 and 100µM) with Western Blot analysis for TFRC and FTH-1. DFO treated cells were also compared to non-treated controls and positive controls (5Gy radiation [XRT] ). All experiments were conducted in triplicate. Subsequently, we developed in vivo tagged buccal xenografts in Nu/Nu mice. Mice were randomly assigned to control, XRT, and DFO groups (n=5/group). XRT mice received 3 fractionated doses of 3 Gy over 10 days. DFO mice received 5 peritumoral injections of DFO (100µM each). Tumor volumes were measured every third day (ANOVA, p ≥ 0.05). After 12 weeks, excised tumors were analyzed with western blot and qPCR.
RESULTS:
In vitro we found that both cell lines downregulated TFRC in response to 100µM DFO, FTH-1 was downregulated in HPV-cells, but was decreased throughout all groups in HPV+ cells (untreated and treated). In vivo, we observed a significant decrease in tumor volume upon addition of DFO and downregulation of FTH-1 was observed and validated with western blot and qPCR in DFO treated tumors.
CONCLUSION:
These results suggest that DFO is not only safe to use in HNSCC, but it may offer a promising chemotherapeutic approach for oncologic management. Additionally, its chemotherapeutic properties can be gauged utilizing unique signature gene patterns of iron mediator expression as biomarkers within varying subtypes of HNSCC. Due to the heterogeneous nature of HNSCC, further studies examining the effects of DFO in a variety of HNSCC subtypes are warranted. 
PURPOSE:
The medial femoral trochlea (MFT) osteochondral free flap is used for articular reconstruction of the scaphoid and lunate. Understanding lower extremity function and patient-reported outcomes (PRO) following MFT harvest is important in evaluating this novel reconstructive option.
METHODS:
Inclusion criteria for this study were MFT harvest for scaphoid or lunate reconstruction by a single surgeon between 2012 and 2017, and post-operative followup exceeding 6 months. Medical records were reviewed for patient (sex, age, BMI) and operative details. Knee range of motion (ROM) was measured using a handheld goniometer. PROs used to assess the knee include IKDC (International Knee Documentation Committee), AKPS (Anterior Knee Pain Scale), KOOS (Knee Injury and Osteoarthritis Outcomes Score) and WOMAC (Western Ontario McMaster Universities Osteoarthritis Index). Patients were asked to return for a physical exam of the knee and to complete patient reported outcomes questionnaires (PROs). For patients unable to come for a physical exam, PROs were offered electronically. Pre-and post-operative data were compared using t-tests to quantify donor site morbidity. PRS Global Open • 2019 Multivariable modeling was used to examine patient factors that may be predictive of donor site outcomes.
RESULTS: 45 patients were included (14 female, 31 male). Mean age was 25.4 (16-40) years and mean BMI was 28.1 (22-40). 17 returned for follow-up physical exam, and 15 had pre-operative PROs available. Mean examination follow-up was 2.6 years, and mean PRO follow-up was 3.2 years. Knee ROM did not differ between the operated and unoperated knee. When comparing pre-and post-operative scores, statistically significant donor site morbidity was detected on KOOS subscales (n=15; Pain: -5.3 points, p=0.002; Activities of Daily Living [ADL]: -2.5 points, p=0.008; Sports and Recreation: -13 points, p=0.002) and WOMAC (n=15; -3.4%, p=0.009). Changes in other scales and subscales were not statistically significant. When controlled for age and sex, higher BMI was predictive of worse postoperative function on the KOOS Pain and Symptoms subscales, as well as WOMAC scale (p<0.05).
CONCLUSIONS:
MFT harvest does not appear to restrict knee ROM after surgery. Most measures of knee function were unaffected or only slightly affected by MFT harvest; however, there may be some clinically significant donor site morbidity in the Sports and Recreation domain. Additionally, patients with higher BMI may be at risk for increased donor site morbidity. University of Utah, Salt Lake City, UT, USA PURPOSE: In the clinic, there are limited treatment strategies for the repair of peripheral nerve injuries, and the majority of off-the-shelf nerve repair devices lack added functionality. Direct repair is among the most commonly performed nerve repair procedures and presently there is no clinical therapeutic available that improves outcomes after direct repair. The objective of this study is to assess the efficacy of local, controlled delivery of FK506 to improve nerve regeneration outcomes in the setting of nerve transection injury and repair.
METHODS: Solvent casting techniques were used to embed FK506 into poly(lactide-co-caprolactone) (PLC) films for the creation of a nerve wrap -drug delivery system that is capable of an extended, localized release of FK506 to injured nerves. In vitro drug rate of release testing and drug bioactivity assays were performed to determine the FK506 release profile and to verify release FK506 bioactivity. A mouse sciatic transection and direct-suture repair model was used to evaluate the effect local, controlled FK506 delivery could have on nerve regeneration outcomes greater than direct-suture repair alone. Animals were sacrificed at 6 weeks for electrophysiological assessment, determination of gastrocnemius muscle mass recovery, and sciatic nerve histological evaluation.
RESULTS:
A linear release (R 2 =0.991) of FK506 for 30+ days was observed for two FK506 loading concentrations (0.01 % and 0.05% w/w of FK506/PLC). The released FK506 matched control FK506 levels of neurite extension in the dorsal root ganglion assay. Relative gastrocnemius muscle weight, relative foot EMG, and total number of axons distal of the repair site were significantly greater in mice treated with the 0.01% FK506 nerve wrap than the non-drug groups. For the 0.05% nerve wraps, the total axon count distal to the repair site was found to be significantly greater, but no significant differences were observed for the other metrics.
CONCLUSION:
Results of this study indicate that extended, localized delivery of FK506 to a mouse sciatic transection and direct repair can improve nerve regeneration outcomes in a sciatic nerve transection and repair model. A dose-dependent response in the nerve regeneration metrics was observed, indicating there is an optimal dose range for local delivery of FK506. 
